Skip to main content

Table 2 Patient Demographics in the Overall Population and in Subgroups Defined by 1 L Drug Class Received

From: Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom

  All patients (n = 1003) 1 L chemotherapy (n = 698) 1 L IO monotherapy (n = 179) 1 L targeted therapy (n = 126)
Proportion of study population, % 100 69.6 17.8 12.6
Median follow-up (range), months 9.2 (0.0–42.7) 7.9 (0.0–42.7) 12.7 (0.1–37.3) 16.3 (0.1–37.1)
Median age at diagnosis (range), years 68 (28–93) 68 (28–88) 67 (48–90) 70 (32–93)
Sex, n (%)
 Male 541 (53.9) 395 (56.6) 94 (52.5) 52 (41.3)
 Female 462 (46.1) 303 (43.4) 85 (47.5) 74 (58.7)
Tumor histology, n (%)
 Adenocarcinoma 635 (63.3) 387 (55.4) 131 (73.2) 117 (92.9)
 Squamous cell carcinoma 243 (24.2) 202 (28.9) 38 (21.2) 3 (2.4)
 Large cell carcinoma 6 (0.6) 4 (0.6) 2 (1.1) 0
 Not specified 119 (11.9) 105 (15.0) 8 (4.5) 6 (4.8)
TNM stage at diagnosis, n (%)
 T
  T X-4 938 (93.5) 647 (92.7) 170 (95.0) 121 (96.0)
  N/A 65 (6.5) 51 (7.3) 9 (5.0) 5 (4.0)
 N
  N X-3 939 (93.6) 648 (92.8) 170 (95.0) 121 (96.0)
  N/A 64 (6.4) 50 (7.2) 9 (5.0) 5 (4.0)
 M
  M1a 524 (52.2) 351 (50.3) 114 (63.7) 59 (46.8)
  M1a 166 (16.6) 120 (17.2) 22 (12.3) 24 (19.0)
  M1b 310 (30.9) 224 (32.1) 43 (24.0) 43 (34.1)
  M1c 3 (0.3) 3 (0.4) 0 0
ECOG PS score at diagnosis, n (%)
 0–1 759 (75.7) 513 (73.5) 157 (87.7) 89 (70.6)
 2+ 244 (24.3) 185 (26.5) 22 (12.3) 37 (29.4)
EGFR+ status, n (%)b
 Documented 19 (1.9) 1 (0.1) 0 18 (14.3)
 Assumed 89 (8.9) 0 0 89 (70.6)
ALK+ status, n (%)b
 Documented 2 (0.2) 0 0 2 (1.6)
 Assumed 17 (1.7) 0 0 17 (13.5)
PD-L1+ status, n (%)b
 Documented 10 (1.0) 3 (0.4) 7 (3.9) 0
 Assumed 172 (17.1) 0 172 (96.1) 0
  1. 1 L first line; ALK anaplastic lymphoma kinase; ECOG PS Eastern Cooperative Oncology Group performance status; EGFR epidermal growth factor receptor; IO immuno-oncology; NSCLC non-small cell lung cancer; PD-L1 programmed death-ligand 1
  2. a Includes 77 patients with clinician-defined stage IV NSCLC. b Biomarker status was based either on hospital test results (documented) or treatment regimen (assumed, ie, patients who received an EGFR or ALK inhibitor were assumed to have a tumor harboring an EGFR or ALK mutation, and patients receiving IO therapy were assumed to have a PD-L1+ tumor)